At the news
? BULLISHIMPACT 6/10 8-K filed Aug 7, 2026 at 07:00 ET
NRx Pharmaceuticals disclosed that the FDA completed first-round review of its ANDA for preservative-free ketamine with no drug-related major deficiencies, but identified a single major deficiency related to the vial's luer lock cap. The FDA committed to reinitiate review in the shortest possible cycle, citing ketamine's status on the drug shortage list. Management expects first commercial sales in 2026 if the packaging issue is resolved.
- ANDA for preservative-free ketamine filed September 2025
- FDA advised July 30, 2026: no major drug-related deficiencies on first-round review
- One major deficiency identified: twist-off cap of luer lock vial (container closure concern)
- Clarification meeting held August 6, 2026 with FDA Office of Generic Drugs and CDER leadership
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access